SiBone (NASDAQ:SIBN) SVP Michael Pisetsky Sells 36,241 Shares of Company Stock

Key Points

• SVP Michael Pisetsky sold 36,241 SiBone shares for about $898,777 at $24.80 per share, reducing his ownership by 47.43% to 40,167 shares.
• SiBone’s latest quarter beat expectations: earnings per share were a loss of $0.08 versus the estimated loss of $0.13, while revenue was $55.7 million versus a $55.31 million estimate.
• Analysts have a consensus “Moderate Buy” rating and a $25 average price target; the stock was trading at $24.24 in Friday’s session.

SiBone (NASDAQ:SIBN - Get Free Report) SVP Michael Pisetsky sold 36,241 shares of the firm's stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $24.80, for a total value of $898,776.80. Following the transaction, the senior vice president owned 40,167 shares of the company's stock, valued at $996,141.60. This trade represents a 47.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

SiBone Trading Down 0.1%

SIBN stock traded down $0.03 during trading on Friday, hitting $24.24. The company had a trading volume of 683,472 shares, compared to its average volume of 638,581. The business has a 50-day moving average of $19.71 and a 200-day moving average of $16.56. SiBone has a one year low of $11.48 and a one year high of $25.92. The stock has a market cap of $1.09 billion, a PE ratio of -78.19 and a beta of 0.64. The company has a current ratio of 7.58, a quick ratio of 7.55 and a debt-to-equity ratio of 0.19.

SiBone (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.05. The firm had revenue of $55.70 million during the quarter, compared to analyst estimates of $55.31 million. SiBone had a negative net margin of 6.20% and a negative return on equity of 7.57%. Research analysts predict that SiBone will post -0.34 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SIBN has been the subject of a number of analyst reports. Truist Financial lifted their target price on shares of SiBone from $23.00 to $25.00 and gave the stock a "buy" rating in a research note on Wednesday, October 14th. Weiss Ratings upgraded shares of SiBone from a "sell (e+)" rating to a "sell (d-)" rating in a report on Thursday, August 20th. Citigroup reaffirmed a "market outperform" rating on shares of SiBone in a research report on Tuesday. Needham & Company LLC decreased their price target on SiBone from $27.00 to $26.00 and set a "buy" rating for the company in a report on Tuesday. Finally, TD Cowen lifted their price objective on SiBone from $20.00 to $23.00 and gave the stock a "buy" rating in a research report on Tuesday. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, SiBone has an average rating of "Moderate Buy" and a consensus target price of $25.00.

Institutional Trading of SiBone

Several large investors have recently modified their holdings of the stock. Versant Capital Management Inc increased its stake in shares of SiBone by 102.9% in the 2nd quarter. Versant Capital Management Inc now owns 1,749 shares of the company's stock valued at $29,000 after acquiring an additional 887 shares in the last quarter. State of Wyoming boosted its stake in SiBone by 70.8% during the first quarter. State of Wyoming now owns 10,832 shares of the company's stock worth $137,000 after acquiring an additional 4,490 shares in the last quarter. Inceptionr LLC bought a new position in SiBone during the first quarter worth $156,000. ADAR1 Capital Management LLC acquired a new stake in SiBone in the first quarter worth $159,000. Finally, Elevation Point Wealth Partners LLC acquired a new stake in SiBone in the first quarter worth $204,000. Institutional investors and hedge funds own 98.11% of the company's stock.

SiBone Company Profile

SI-BONE, Inc NASDAQ: SIBN is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.

Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.